Knight Obtains Impavido Worldwide Rights
MONTREAL, QUEBEC–(Marketwired – Mar 15, 2016) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it now owns worldwide rights to Impavido® (miltefosine) as a result of the termination of its agreement with Paladin Labs (Barbados) Inc., (an affiliate of Endo International plc) related to the distribution and sale […]
Knight Breaks Glass on Medimetriks Partnership
MONTREAL, CANADA and NEW JERSEY, UNITED STATES–(Marketwired – Feb 17, 2016) – Knight Therapeutics Inc. (TSX:GUD) (Knight) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) announced today that Knight has agreed to issue a secured loan of up to US$20 million to support Medimetriks’ acquisition of the exclusive U.S. development and commercialization rights for OPA-15406 from Otsuka Pharmaceutical […]
INTEGA Skin Looks GUD to Knight
MONTREAL, QUEBEC–(Marketwired – Jan 25, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured loan agreement with INTEGA Skin Sciences Inc. (“INTEGA”), a new Montreal-based skincare company aspiring to become a benchmark in the pharmaceutical industry in the treatment and care of […]
Knight Loan to Extenway Impaired
MONTREAL, CANADA–(Marketwired – Dec 22, 2015) – Extenway Solutions Inc. (“Extenway”) announced yesterday that a receiver was appointed over the majority of its assets under direction from Caisse Desjardins de Beauport, another secured creditor. Knight Therapeutics Inc. (TSX:GUD) (“Knight”) entered into a secured loan of $800,000 with Extenway in June 2015 which is currently outstanding. […]
Knight Takes Right Angle With 60 Degrees Pharmaceuticals LLC
MONTREAL, CANADA–(Marketwired – Dec 11, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it has extended the first tranche of a fully secured loan of up to US$4 Million to 60° Pharmaceuticals LLC (“60P”). The loan proceeds will allow 60P to continue the development of medicines for […]
CRH Makes GUD on Knight Secured Loan
MONTREAL, CANADA–(Marketwired – Nov 25, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced that later today it will successfully exit its investment in CRH Medical Corporation (TSX:CRH)(NYSE:CRHM) (“CRH”) following early repayment of the remaining balance of US$22.0 million on its secured loan to CRH. In December of 2014, Knight […]
Knight to Present at the TD Securities Technology & Healthcare Conference in Toronto
MONTREAL, CANADA–(Marketwired – Nov 17, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the TD Securities Technology & Healthcare Conference on Friday, November 20, 2015 at 10:00 am ET at the St. Andrew’s […]
Knight Supports Operation Antibe
MONTREAL, QUEBEC–(Marketwired – Nov 16, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has purchased $500,000 of senior secured convertible debentures (the “Debentures”) offered by Antibe Therapeutics Inc. (“Antibe”) (TSX VENTURE:ATE)(OTCQX:ATBPF) as part of a $2.6 million private placement. The proceeds will be used to further […]
Knight Partner FOCUSed on Growth
MONTREAL, CANADA–(Marketwired – Nov 16, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it has agreed to extend an additional secured loan of US$5.5 million to Synergy CHC Corp. (OTCQB:SNYR) (“Synergy”). The secured loan will support Synergy’s acquisition of Flat Tummy Tea and UrgentRx™, two established brands […]
Knight Reports Third Quarter Financial 2015 Results
MONTREAL, CANADA–(Marketwired – Nov 11, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported its third quarter ended September 30, 2015 financial results. Third Quarter 2015 Highlights Product Development Entered into an exclusive Canadian distribution agreement with Alimera Sciences, Inc. for ILUVIEN®, a sustained release intravitreal […]
